Distinct shared and compartment-enriched oncogenic networks drive primary versus metastatic breast cancer

Zhe Jiang,YoungJun Ju,Amjad Ali,Philip E. D. Chung,Patryk Skowron,Dong-Yu Wang,Mariusz Shrestha,Huiqin Li,Jeff C. Liu,Ioulia Vorobieva,Ronak Ghanbari-Azarnier,Ethel Mwewa,Marianne Koritzinsky,Yaacov Ben-David,James R. Woodgett,Charles M. Perou,Adam Dupuy,Gary D. Bader,Sean E. Egan,Michael D. Taylor,Eldad Zacksenhaus
DOI: https://doi.org/10.1038/s41467-023-39935-y
IF: 16.6
2023-07-18
Nature Communications
Abstract:Abstract Metastatic breast-cancer is a major cause of death in women worldwide, yet the relationship between oncogenic drivers that promote metastatic versus primary cancer is still contentious. To elucidate this relationship in treatment-naive animals, we hereby describe mammary-specific transposon-mutagenesis screens in female mice together with loss-of-function Rb , which is frequently inactivated in breast-cancer. We report gene-centric common insertion-sites (gCIS) that are enriched in primary-tumors, in metastases or shared by both compartments. Shared-gCIS comprise a major MET-RAS network, whereas metastasis-gCIS form three additional hubs: Rho-signaling, Ubiquitination and RNA-processing. Pathway analysis of four clinical cohorts with paired primary-tumors and metastases reveals similar organization in human breast-cancer with subtype-specific shared-drivers (e.g. RB1-loss, TP53-loss, high MET, RAS, ER), primary-enriched (EGFR, TGFβ and STAT3) and metastasis-enriched (RHO, PI3K) oncogenic signaling. Inhibitors of RB1-deficiency or MET plus RHO-signaling cooperate to block cell migration and drive tumor cell-death. Thus, targeting shared- and metastasis- but not primary-enriched derivers offers a rational avenue to prevent metastatic breast-cancer.
multidisciplinary sciences
What problem does this paper attempt to address?